Sales Force Effectiveness Russia-CIS

eyeforpharma7-8 October, 2008, Moscow, Russia
These two intensive days address the most important aspects of SFE in Russia and CIS region. Following on from years of highly successful Global Pharmaceutical Sales conferences eyeforpharma's latest offering in this field guarantees the insights, strategies and contacts to drive sales growth and measure ROI in complex and changing environment.

  • Superb networking: Unprecedented opportunities for you to meet, discuss and debate with your pharma peers and the industries most innovative thinkers.
  • Groundbreaking case studies: Cutting edge and insightful case studies from market-leading pharma companies.
  • Interactive roundtables: For the first time eyeforpharma deliver a series of thought-provoking discussion forums designed to drill down into the business critical issues that matter to you most .
  • In-depth workshops: Unique expert analysis and delegate participation ensuring you take away blueprints for successful sales force strategies.

The summit includes industry led workshops, roundtable discussions, pre-day IMS workshop and over 25 senior level speakers.

Hosting 25 speakers-key notes include:

  • Patrick Aghanian General Manager Russia-CIS, Sandoz
  • Paul Kusters Director SFE & Training Europe, UCB-Group
  • Milos Petrovic General Manager Russia-CIS, Roche
  • Marc Widmer Sales Excellence Director Russia, sanofi-aventis
  • Sergei Dereviannykh, Sales Excellence, Director Russia-CIS, Organon- Schering-Plough
  • Eugene Zaika Head of Representative Office Ukraine and Maldova, Nycomed

For more information visit http://www.eyeforpharma.com/salesrussia08/

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. For more information, please visit www.eyeforpharma.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...